Who is eligible for clinical trial NCT06422884?

Participants must meet the protocol's inclusion criteria for Idiopathic Pulmonary Fibrosis. The stated age range is 40 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06422884 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-20

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) (NCT06422884)

A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Endeavor Biomedicines, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (28 items).

Location: Research Site — Quilmes, Buenos Aires

Age range: 40 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Patients ≥ 40 years old with an IPF diagnosis as confirmed by the Investigator.
Percent predicted FVC of ≥ 45% at study start.
Percent predicted diffusing capacity of lung for carbon monoxide (DLCO) ≥ 25%, adjusted for hemoglobin (Hgb) at study start.
Ability to perform spirometry tests.
Either stable treatment with standard of care (SoC) \[i.e., antifibrotics, immunosuppressants (PPF only)\] for at least 3 months prior to study start or not treated with SoC for at least 8 weeks prior to study start.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Evidence of other known causes of interstitial lung disease (ILD).
Forced expiratory volume in one second (FEV1)/FVC ratio \<0.7 at study start.
History of malignancy, including carcinoma during the preceding 5 years from study start, with the following exceptions:
Prior history of in situ melanoma, basal or squamous cell skin cancer if treated with curative therapy.
Patients with prostate cancer that are managed by surveillance.
Patients with ductal carcinoma in situ, treated surgically with curative intent.
Patients with moderate to severe hepatic impairment (Child-Pugh B and C).
Smoking (including vaping) within 6 months of study start; current smoker, or unwillingness to refrain from smoking during the clinical trial duration.
Active or suspected alcohol or drug abuse in the opinion of the Investigator.
Currently enrolled in another investigational device or drug trial, or less than 3 months from study start since ending another investigational device or drug trial(s) or receiving other investigational treatment(s).
Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV).

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (78 Sites)

Showing the first 25 of 78 sites.

Research Site — Quilmes, Buenos Aires
Research Site — Buenos Aires,
Research Site — Buenos Aires,
Research Site — Mendoza,
Research Site — Mendoza,
Research Site — Camperdown, New South Wales
Research Site — Macquarie Park, New South Wales
Research Site — Brisbane, Queensland
Research Site — South Brisbane, Queensland
Research Site — Box Hill, Victoria
Research Site — Nedlands, Western Australia
Research Site — Graz, Styria
Research Site — Vienna,
Research Site — Dinant, Namur
Research Site — Brussels,
Research Site — Brussels,
Research Site — Edmonton, Alberta
Research Site — Vancouver, British Columbia
Research Site — Ajax, Ontario
Research Site — Montreal, Quebec
Research Site — Sherbrooke, Quebec
Research Site — Trois-Rivières, Quebec
Research Site — Angers,
Research Site — Bordeaux,
Research Site — Caen,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Idiopathic Pulmonary Fibrosis

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis — Windsor, Ontario
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis — Worcester, Massachusetts
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF — St John's,

Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗